BiomX to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Rhea-AI Summary

BiomX Inc. (NYSE American: PHGE), a clinical-stage company developing novel phage therapies targeting specific pathogenic bacteria, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024, at the Lotte New York Palace Hotel.

Key details include:

• CEO Jonathan Solomon will present a corporate overview
• Presentation Date: September 9, 2024
• Time: Available on-demand from 7:00 AM ET
• Webcast link provided for virtual attendance
• Replay available on BiomX's website for 90 days

Mr. Solomon will also be available for one-on-one meetings during the conference. Interested parties can register and request meetings through the provided link.

GAITHERSBURG, Md., Sept. 04, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announces today that Jonathan Solomon, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 26^th Annual Global Investment Conference. The conference is being held on September 9 - 11, 2024 at the Lotte New York Palace Hotel.

Presentation Date:		September 9, 2024
Time:		Available on-demand starting at 7:00 AM ET
Webcast Link:		https://journey.ct.events/view/d258dc7c-4d95-483c-9e0e-be6af1e9343d

A replay of the presentation can be found on the Company’s website under Events & Presentations and will be available for 90 days: https://ir.biomx.com/news-events

Mr. Solomon will be available for one-on-one meetings throughout the conference. To request a meeting and to register for the conference, click here: https://hcwevents.com/annualconference/

About BiomX
BiomX is a clinical-stage company leading the development of natural and engineered phage cocktails and personalized phage treatments designed to target and destroy harmful bacteria for the treatment of chronic diseases with substantial unmet needs. BiomX discovers and validates proprietary bacterial targets and applies its BOLT (“BacteriOphage Lead to Treatment”) platform to customize phage compositions against these targets. For more information, please visit www.biomx.com, the content of which does not form a part of this press release.

Contacts:
BiomX, Inc.
Assaf Oron
+97254-2228901
assafo@biomx.com

INVESTORS:
CORE IR
Peter Seltzberg
peters@coreir.com

FAQ

When is BiomX (PHGE) presenting at the H.C. Wainwright Global Investment Conference?

BiomX (PHGE) is presenting at the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024. The presentation will be available on-demand starting at 7:00 AM ET.

Where can I watch the BiomX (PHGE) presentation from the H.C. Wainwright conference?

You can watch the BiomX (PHGE) presentation via the webcast link provided in the press release. A replay will also be available on the BiomX website under Events & Presentations for 90 days after the conference.

What is the focus of BiomX's (PHGE) research and development?

BiomX (PHGE) is a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria.

How can investors arrange meetings with BiomX (PHGE) management at the H.C. Wainwright conference?

Investors can request one-on-one meetings with BiomX (PHGE) CEO Jonathan Solomon by registering for the conference through the provided link: https://hcwevents.com/annualconference/